Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J's EmboTrap Clot Retriever Gets US Green Light

Executive Summary

Johnson & Johnson has added the Embotrap clot retrieval device to its US offering after the product got FDA clearance. It will compete with Medtronic's Solitaire and Stryker's Trevo, which are already on the US market.

You may also be interested in...



Johnson & Johnson Growth Led By Biosense Webster And Cerenovus

Johnson & Johnson’s leadership remains optimistic about the future of its medical device divisions despite reporting a 2.6% revenue decline in the first six months of 2019 compared to the same period of 2018.

ISC 2018: ARISE II Supports J&J's EmboTrap Stent-Retriever

The International Stroke Conference in Los Angeles featured new data that will support an FDA submission for J&J/Cerenovous' EmboTrap revascularization device. The findings showed a high rate of "first-pass" effectiveness and EmboTrap was successful in creating final substantial reperfusion in 90% of the treated patients.

Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?

Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

MT122679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel